Clinical Trials
5 trialsNCT00958074 2018-10-18
Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma
University of Washington
Phase 2 Terminated
NCT01187446 2017-11-20
Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides
Stanford University
Phase 1/2 Terminated
NCT00601718 2017-05-25
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
University of Washington
Phase 1/2 Completed
NCT00005634 2013-06-19
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT01116154 2010-12-09
Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
City of Hope Medical Center
Phase 1 Terminated